Animal Component-Free Cell Dissociation Kit

Dissociation kit for human stem and progenitor cells

Animal Component-Free Cell Dissociation Kit

Dissociation kit for human stem and progenitor cells

From: 223 USD
Catalog #
(Select a product)
Dissociation kit for human stem and progenitor cells
Add to Wish List

Product Advantages


  • Optimized for the dissociation and passaging of human stem
    and progenitor cells

  • Obtain cleaner cultures with ready-to-use, animal component-free solutions

What's Included

  • ACF Enzymatic Dissociation Solution, 250 mL
  • ACF Enzyme Inhibition Solution, 250 mL

Overview

Use Animal Component-Free Dissociation Kit for dissociating and passaging human stem and progenitor cells. Compatible with cells cultured in various media formulations, this kit comes with ready-to-use solutions, including ACF Enzymatic Dissociation Solution and ACF Enzyme Inhibition Solution.

Previously known as MesenCult™-ACF Dissociation Kit, this kit's name was changed to accommodate the use of this product with other cell types such as endothelial cells, HUVECs, mesenchymal cells, PSC-derived cells, mesenchymal stem and progenitor cells, and myogenic stem and progenitor cells.
Subtype
Enzymatic
Cell Type
Endothelial Cells, Endothelial Colony Forming Cells (ECFCs), HUVECs, Mesenchymal Cells, PSC-Derived, Mesenchymal Stem and Progenitor Cells, Myogenic Stem and Progenitor Cells
Species
Human
Application
Cell Culture
Brand
MesenCult
Area of Interest
Endothelial Cell Biology, Stem Cell Biology

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
05426
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
05426
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
05426
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (2)

Focal adhesion protein abnormalities in myelodysplastic mesenchymal stromal cells. Aanei CM et al. Experimental cell research 2011 NOV

Abstract

Direct cell-cell contact between haematopoietic progenitor cells (HPCs) and their cellular microenvironment is essential to maintain 'stemness'. In cancer biology, focal adhesion (FA) proteins are involved in survival signal transduction in a wide variety of human tumours. To define the role of FA proteins in the haematopoietic microenvironment of myelodysplastic syndromes (MDS), CD73-positive mesenchymal stromal cells (MSCs) were immunostained for paxillin, pFAK [Y(397)], and HSP90α/β and p130CAS, and analysed for reactivity, intensity and cellular localisation. Immunofluorescence microscopy allowed us to identify qualitative and quantitative differences, and subcellular localisation analysis revealed that in pathological MSCs, paxillin, pFAK [Y(397)], and HSP90α/β formed nuclear molecular complexes. Increased expression of paxillin, pFAK [Y(397)], and HSP90α/β and enhanced nuclear co-localisation of these proteins correlated with a consistent proliferative advantage in MSCs from patients with refractory anaemia with excess blasts (RAEB) and negatively impacted clonogenicity of HPCs. These results suggest that signalling via FA proteins could be implicated in HPC-MSC interactions. Further, because FAK is an HSP90α/β client protein, these results suggest the utility of HSP90α/β inhibition as a target for adjuvant therapy for myelodysplasia.
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Dominici M et al. Cytotherapy 2006 JAN

Abstract

The considerable therapeutic potential of human multipotent mesenchymal stromal cells (MSC) has generated markedly increasing interest in a wide variety of biomedical disciplines. However, investigators report studies of MSC using different methods of isolation and expansion, and different approaches to characterizing the cells. Thus it is increasingly difficult to compare and contrast study outcomes, which hinders progress in the field. To begin to address this issue, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC. First, MSC must be plastic-adherent when maintained in standard culture conditions. Second, MSC must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR surface molecules. Third, MSC must differentiate to osteoblasts, adipocytes and chondroblasts in vitro. While these criteria will probably require modification as new knowledge unfolds, we believe this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.